Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
“Not Just a Science Experiment”: Ripple CEO Says Tokenization Has Grown Up

“Not Just a Science Experiment”: Ripple CEO Says Tokenization Has Grown Up

CoinEditionCoinEdition2026/02/04 10:24
By:CoinEdition

Ripple CEO Brad Garlinghouse says tokenization is no longer just a theory or a tech experiment, arguing that real momentum is finally building across global markets.

Tokenized assets on Ripple’s XRP Ledger jumped more than 2,200% last year, a sign that institutions are starting to move beyond pilot projects and into real use.

He pointed to stablecoins as the clearest early success. “The first poster child of tokenization was really stablecoins,” Garlinghouse said, saying that transaction volumes surged sharply. By industry estimates, stablecoin transactions rose from about $19 trillion in 2024 to $33 trillion in 2025, roughly 75% growth in a single year.

Garlinghouse also dismissed the idea that crypto would replace national currencies, saying governments are unlikely to surrender control over money.

“The sovereignty of fiat currencies is, for many countries, sacrosanct,” he said, recalling a remark from a former central banker who once warned that governments would “roll tanks into the streets” before giving up control of monetary supply.

Instead of replacing existing systems, Garlinghouse said Ripple is focused on connecting them, building what he described as bridges between traditional finance and blockchain-based networks by working directly with banks and financial institutions.

Garlinghouse said momentum has changed as political attitudes toward crypto in the United States have shifted.

“For a long time, the US was pretty openly hostile to parts of crypto and blockchain,” he said. That stance, he added, has changed, beginning at the White House and extending into Congress, giving the industry more confidence to build domestically.

Still, Garlinghouse warned that not every asset should be tokenized just for the sake of it.

“We shouldn’t tokenize everything just to tokenize something,” he said. “There has to be a positive outcome, efficiency, transparency, otherwise it’s just a science experiment.”

(adsbygoogle = window.adsbygoogle || []).push({});

That distinction matters as tokenization begins to move into physical commodities.

In a recent example, more than $280 million worth of polished diamonds were recorded on a blockchain using Ripple-developed technology. The project is one of the largest known attempts to digitally represent diamonds. 

As Garlinghouse put it, the real test for tokenization is no longer whether it works in theory, but whether it delivers results in the real economy.

Related: How Will XRP Price Perform in February 2026? Insights from ChatGPT, Claude, and Grok

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Cyclical stocks always peak when they're “cheapest” — Citrini, the “chip influencer” who was the earliest to be bullish on AI hardware, is now quietly exiting

Citrini, once the most prominent bull in AI hardware, has now significantly reduced his semiconductor holdings and currently holds some short positions. He believes that the financing structure for AI infrastructure has shifted from tech giants' own cash flows to equity and debt markets, and that sentiment alone could sever the funding chain and impact fundamentals. Strategically, he is long Meta and short Google. Citrini also asserts that the bottleneck in AI pharmaceutical development is not computational power, but rather a "lack of monkeys."

华尔街见闻•2026/10/26 03:36
Cyclical stocks always peak when they're “cheapest” — Citrini, the “chip influencer” who was the earliest to be bullish on AI hardware, is now quietly exiting

Median survival prolonged by 5.7 months! Roche (RHHBY.US) lung cancer new drug wins in head-to-head trial, major catalyst for oncology business

Roche's investigational lung cancer drug divarasib extended patient survival by nearly six months compared to competing therapies in a late-stage clinical trial, promising to further strengthen the Swiss pharmaceutical company's oncology portfolio.

智通财经•2026/10/26 03:11

Global Aging Reshapes Equity and Bond Investment Logic? Pension "Longevity Bill" Accelerates Accumulation, Equities, Bonds, and Private Equity Welcome Massive Long-term Capital

As people live longer and birth rates decline, pension funds are required to allocate their assets for retirement periods that can last decades. Meanwhile, the number of workers contributing to these systems is decreasing.

智通财经•2026/10/26 02:43